Provided by Tiger Fintech (Singapore) Pte. Ltd.

LISATA THERAPEUTICS INC

2.53
+0.09003.69%
Post-market: 2.48-0.0500-1.98%16:00 EDT
Volume:9.60K
Turnover:23.51K
Market Cap:21.27M
PE:-1.05
High:2.53
Open:2.43
Low:2.31
Close:2.44
Loading ...

Will Lisata Therapeutics (NASDAQ:LSTA) Spend Its Cash Wisely?

Simply Wall St.
·
26 Apr

BRIEF-Lisata Therapeutics- Will Evaluate Efficacy Of Certepetide

Reuters
·
15 Apr

Lisata Therapeutics- Will Evaluate Efficacy of Certepetide, as Payload in Context of Catalent's Smartag ADC Dual-Payload Technology Platform

THOMSON REUTERS
·
15 Apr

Lisata Therapeutics Announces Research License with Catalent

GlobeNewswire
·
15 Apr

Press Release: Bladex and Scotiabank lead US$100 million loan for EGE Haina

Dow Jones
·
14 Mar

Lisata Therapeutics Inc (LSTA) Q4 2024 Earnings Call Highlights: Promising Developments Amid ...

GuruFocus.com
·
28 Feb

Lisata Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
28 Feb

Lisata Therapeutics Inc: Cash Runway Extending Into Q2 of 2026 With No Debt

THOMSON REUTERS
·
28 Feb

Lisata Therapeutics Inc expected to post a loss of 76 cents a share - Earnings Preview

Reuters
·
26 Feb

BTN's Sustainable Finance Framework Receives Excellent Rating from Sustainable Fitch

Tempo
·
23 Feb

Lisata Therapeutics and Warpnine Announce Encouraging Preliminary Results From the Phase 1B/2a Ilsta Trial Evaluating Certepetide in Locally Advanced Non-Resectable Pancreatic Ductal Adenocarcinoma

THOMSON REUTERS
·
23 Jan

Lisata Therapeutics Shares Tumble After Pancreatic Cancer Treatment Results

Dow Jones
·
23 Jan

US Stocks Higher; Netflix Profit Beats Estimates

Benzinga
·
22 Jan

Lisata Therapeutics reports preliminary Cohort A data from Phase 2 ASCEND trial

TIPRANKS
·
22 Jan

Lisata Therapeutics Inc - Data From Cohort B Expected in Coming Months

THOMSON REUTERS
·
22 Jan

Lisata Therapeutics - Positive Trend in Overall Survival With 4 Complete Responses Related to Ongoing Phase 2 Ascend Trial

THOMSON REUTERS
·
22 Jan

Lisata Therapeutics Reports Encouraging Preliminary Cohort A Data from the AGITG-led Phase 2 ASCEND Trial Evaluating Certepetide with Standard-of-Care Chemotherapy in Metastatic Pancreatic Ductal Adenocarcinoma

GlobeNewswire
·
22 Jan

Beat the Market the Zacks Way: SoFi Technologies, Lisata Therapeutics, AutoZone in Focus

Zacks
·
06 Jan

Lisata Therapeutics Completes Enrollment for Cancer Therapy Trial

Exec Edge
·
11 Dec 2024

Lisata Therapeutics Announces Completion of Enrollment in the Cendifox Trial

THOMSON REUTERS
·
10 Dec 2024